Medtronic’s Hold Rating: Balancing Promising Innovations with Market Challenges

BTIG analyst Ryan Zimmerman has maintained their neutral stance on MDT stock, giving a Hold rating on October 8.

Ryan Zimmerman has given his Hold rating due to a combination of factors surrounding Medtronic’s current market position and future growth prospects. The company is making strides in its Pelvic Health segment with the introduction of the Altaviva device, which is seen as a potential growth driver in the coming years. However, the success of this initiative depends on establishing a robust reimbursement infrastructure, which may take time to develop.
Additionally, while Medtronic has a promising pipeline with projects like Affera and Hugo, its growth has been limited by challenges in more established markets. The company’s inability to achieve growth beyond 5% has affected its stock valuation, and its shares are expected to remain constrained until more long-term targets are provided. Despite efforts to optimize its portfolio and improve profitability, particularly with the potential divestiture of its Diabetes segment, these changes are not expected to fully materialize until FY27. Therefore, the Hold rating reflects a cautious outlook until clearer growth trajectories are established.

According to TipRanks, Zimmerman is an analyst with an average return of -2.3% and a 40.08% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, PROCEPT BioRobotics, and Hologic.

In another report released on October 8, Stifel Nicolaus also maintained a Hold rating on the stock with a $105.00 price target.